AbCellera Biologics (ABCL) Aktienübersicht
AbCellera Biologics Inc. beschäftigt sich mit der Entdeckung und Entwicklung von Medikamenten auf Antikörperbasis für Indikationen mit ungedecktem medizinischen Bedarf in den Vereinigten Staaten. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 0/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
Belohnungen
Risikoanalyse
ABCL Community Fair Values
Create NarrativeSee what 106 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
AbCellera Biologics Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$10.89 |
| 52-Wochen-Hoch | US$12.58 |
| 52-Wochen-Tief | US$2.75 |
| Beta | 1.32 |
| 1 Monat Veränderung | -0.73% |
| 3 Monate Veränderung | 107.82% |
| 1 Jahr Veränderung | 143.62% |
| 3 Jahre Veränderung | 103.93% |
| 5 Jahre Veränderung | -46.51% |
| Veränderung seit IPO | -81.51% |
Aktuelle Nachrichten und Updates
Narrative-Update • Sep 08
ABCL: Menopause Program Hype And Jazz Deal Will Eventually Face Reality
Analysts lifted their fair value estimate for AbCellera Biologics from $7.00 to $9.00 and referenced sharply higher price targets of $25 and $30 that are linked to stronger confidence in ABCL635 and recent partnership progress. Analyst Commentary on AbCellera Biologics Recent research coverage on AbCellera Biologics has focused on two areas.
Narrative-Update • Aug 24
ABCL: Menopause Program Progress And Jazz Deal Will Drive Future Upside
AbCellera Biologics' fair value estimate has moved from $13.00 to $30.00, as analysts point to stronger perceived potential for ABCL635 in menopausal vasomotor symptoms following Phase 2 data and updated projections for a multibillion dollar market opportunity. Analyst Commentary Recent Street research on AbCellera Biologics has shifted firmly toward a more constructive view, with several bullish analysts revisiting their price frameworks following the latest Phase 2 data for ABCL635 in menopausal vasomotor symptoms and the new collaboration activity.Recent updates
Narrative-Update • Sep 08
ABCL: Menopause Program Hype And Jazz Deal Will Eventually Face Reality
Analysts lifted their fair value estimate for AbCellera Biologics from $7.00 to $9.00 and referenced sharply higher price targets of $25 and $30 that are linked to stronger confidence in ABCL635 and recent partnership progress. Analyst Commentary on AbCellera Biologics Recent research coverage on AbCellera Biologics has focused on two areas.Narrative-Update • Aug 24
ABCL: Menopause Program Progress And Jazz Deal Will Drive Future Upside
AbCellera Biologics' fair value estimate has moved from $13.00 to $30.00, as analysts point to stronger perceived potential for ABCL635 in menopausal vasomotor symptoms following Phase 2 data and updated projections for a multibillion dollar market opportunity. Analyst Commentary Recent Street research on AbCellera Biologics has shifted firmly toward a more constructive view, with several bullish analysts revisiting their price frameworks following the latest Phase 2 data for ABCL635 in menopausal vasomotor symptoms and the new collaboration activity.Seeking Alpha • Aug 11
AbCellera: Excellent Phase 2 Data In Menopause But The Platform Narrative Is Fading
Summary AbCellera Biologics has shifted from a pure platform-for-hire to developing its own pipeline, notably ABCL635 for menopausal vasomotor symptoms. ABCL635, a monoclonal antibody targeting NK3R, offers monthly dosing versus daily oral competitors, with Phase 2 data showing strong efficacy at four weeks. Cross-trial comparisons suggest ABCL635's efficacy is promising, but small sample size and early-stage data limit the strength of 'best-in-class' claims. The safety profile is encouraging but not definitive; a transaminase elevation in one patient raises caution, echoing early signals seen in competitor drugs. Read the full article on Seeking Alpha
Narrative-Update • Aug 10
ABCL: Menopause Antibody Data Will Drive Bullish Repricing In Coming Years
Analysts have lifted their fair value estimate for AbCellera Biologics from $10.43 to $14.63, citing higher Street price targets tied to positive ABCL635 Phase 2 data and expectations for future revenue from the new Jazz Pharmaceuticals development agreement. Analyst Commentary Street research on AbCellera Biologics has turned more constructive in recent months, with several firms adjusting ratings and price targets following clinical and partnership updates.Analyseartikel • Aug 10
AbCellera Biologics Inc. (NASDAQ:ABCL) Analysts Just Slashed This Year's Revenue Estimates By 22%
Today is shaping up negative for AbCellera Biologics Inc. ( NASDAQ:ABCL ) shareholders, with the analysts delivering a...Narrative-Update • Jul 09
ABCL: Jazz Deal And Menopause Program Will Support A Stronger Outlook
The analyst fair value estimate for AbCellera Biologics has been raised from $12.00 to $13.00 as analysts point to the new Jazz Pharmaceuticals agreement, recent rating upgrades, and a more constructive view on the company's long term earnings potential, despite lower modeled revenue growth and a higher future P/E assumption. Analyst Commentary Bullish analysts covering AbCellera Biologics are highlighting the recent agreement with Jazz Pharmaceuticals as an important proof point for the company’s partnership model and revenue opportunity.Narrative-Update • Jun 25
ABCL: Menopause Phase 2 Progress Will Shape Future Upside Potential
Analysts have lifted their price target on AbCellera Biologics by $1, citing recent bullish coverage and views that the company’s profile compares favorably with certain peers as key reasons for the change. Analyst Commentary Recent research on AbCellera Biologics points to a generally positive tone, with several bullish initiations and a modest price target increase that together shape how analysts are thinking about the stock’s valuation, growth potential, and execution risks.Narrative-Update • Jun 10
ABCL: Menopause Phase 2 Progress Will Support Future Margin Expansion
The analyst price target on AbCellera Biologics has been raised by $1. Analysts cite updated fair value estimates, a slightly lower discount rate, revised revenue growth expectations, and a very large projected future P/E multiple as key drivers of the change.Narrative-Update • May 26
ABCL: GPCR Platform Progress And Upcoming Women’s Health Data Will Drive Upside
Analysts lifted their price target on AbCellera Biologics by $1, citing recent bullish initiations and research that view the company’s profile as increasingly attractive relative to selected peers. Analyst Commentary Recent Street research on AbCellera Biologics highlights a mix of optimism and caution, with several firms updating their views and price targets in light of the company’s current positioning and peer comparisons.Analyseartikel • May 14
Earnings Update: Here's Why Analysts Just Lifted Their AbCellera Biologics Inc. (NASDAQ:ABCL) Price Target To US$10.14
AbCellera Biologics Inc. ( NASDAQ:ABCL ) investors will be delighted, with the company turning in some strong numbers...Narrative-Update • May 06
ABCL: Platform And Partnerships Will Support Future Upside From GPCR Pipeline Progress
The analyst price target for AbCellera Biologics has shifted to $7.00, with analysts pointing to updated assumptions around the discount rate, revenue growth, profit margins, and a very large future P/E multiple. This view is supported by recent bullish Street coverage that frames the company as increasingly attractive relative to certain peers.Narrative-Update • Apr 20
ABCL: Platform And Partnerships Will Support Future Upside Potential
Analysts have adjusted their price target on AbCellera Biologics to $7.00. The change reflects updated assumptions around revenue trends, profit margins, discount rates, and future P/E, supported by recent research that takes a bullish view on the stock.Narrative-Update • Apr 06
ABCL: Menopause Phase 2 Progress Will Support Future Upside Potential
Analysts maintained their $7.00 price target for AbCellera Biologics, citing only very small adjustments to assumptions around discount rate, revenue trends, profit margin, and future P/E as the basis for keeping their overall valuation view steady. What's in the News AbCellera Biologics has started dosing patients in the Phase 2 portion of its ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narrative-Update • Mar 22
ABCL: Menopause Trial Progress Will Drive Future Share Price Upside
Analysts have trimmed their price targets on AbCellera Biologics to $7.00, citing updated assumptions for revenue growth, profit margins and a higher future P/E multiple that together point to a more cautious outlook on how quickly the business may scale. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narrative-Update • Mar 08
ABCL: Patent Settlement And Menopause Trial Will Support A Stronger Outlook
Analysts have lowered their price target on AbCellera Biologics from $15.88 to $12.00, reflecting updated views on fair value, revenue growth expectations, and future P/E assumptions. What's in the News The first patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause (Key Developments).Narrative-Update • Feb 22
ABCL: Menopause Phase 2 Progress And Bruker Settlement Will Support Future Margins
Analysts have maintained their $9.83 price target on AbCellera Biologics, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which they view as collectively balanced at this stage. What's in the News AbCellera began dosing patients in the Phase 2 portion of its ongoing Phase 1/2 trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narrative-Update • Feb 08
ABCL: Clinical Progress And Royalty Deal Will Drive Future Share Price Upside
Analysts have reduced their price target on AbCellera Biologics, citing updated assumptions that incorporate higher expected revenue growth and profit margins, partially offset by a lower projected future P/E multiple. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narrative-Update • Jan 24
ABCL: Phase 2 Menopause Trial Progress Will Support Future Profit Margins
Analysts have trimmed their price target on AbCellera Biologics to US$9.83, reflecting slightly lower discount rate assumptions, a modestly higher long term profit margin outlook, and a small adjustment to future P/E expectations. What's in the News First patients have been dosed in the Phase 2 portion of AbCellera's ongoing Phase 1/2 clinical trial for ABCL635, a potential first in class non hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.Narrative-Update • Jan 08
ABCL: Patent Settlement Cash Flows Will Support A Stronger Future Outlook
Analysts have trimmed their implied fair value estimate for AbCellera Biologics from about US$17.00 to roughly US$15.88, reflecting updated assumptions around discount rates, revenue growth, profit margins, and future P/E levels. What's in the News AbCellera reached a global settlement and patent license agreement with Bruker Corporation, resolving ongoing patent litigation between the two companies (Key Developments).Narrative-Update • Dec 14
ABCL: Higher Future Earnings Multiple Will Drive Strong Share Price Upside
Analysts have raised their price target on AbCellera Biologics by approximately 40 percent to reflect a higher fair value estimate of around 7 dollars per share. They cite expectations for modestly slower revenue growth, offset by improved profit margins and a richer future earnings multiple.Narrative-Update • Nov 29
ABCL: Upcoming Clinical Trial Results Will Drive Future Profit Margins Higher
Analysts have adjusted their price target for AbCellera Biologics slightly downward from $10.20 to $9.83 per share. This change reflects more conservative expectations around future revenue growth and profit margins.Narrative-Update • Nov 15
ABCL: Upcoming Clinical Trial Results Are Expected To Drive Profit Margins Higher
Analysts have raised their price target for AbCellera Biologics from $9.33 to $10.20 per share, citing improved profit margin forecasts even though revenue growth expectations have slightly moderated. What's in the News AbCellera Biologics has begun dosing the first participants in a Phase 1 clinical trial for ABCL575, an investigational antibody therapy aimed at treating moderate to severe atopic dermatitis with potential applications in other inflammatory and autoimmune conditions (Key Developments).Neues Narrative • May 18
Phase I Trials And Manufacturing Will Unlock Pipeline Potential
Transition to a clinical-stage biotech and internal programs could drive revenue through milestone fees and royalty payments from new molecules.Analyseartikel • May 15
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates
The latest analyst coverage could presage a bad day for AbCellera Biologics Inc. ( NASDAQ:ABCL ), with the analysts...Seeking Alpha • Apr 17
AbCellera: Attractively Priced But A Catalyst Is Needed
Summary AbCellera's stock remains under pressure due to a shift towards internal development, which has reduced revenue and increased cash burn. AbCellera retains a large cash position, though, giving it a multi-year runway in which to demonstrate the merits of its platform. AbCellera's low enterprise value suggests that investors are either skeptical of the company's platform or ignoring its cash position. A more favorable macro environment and clinical success will likely be needed before AbCellera's stock moves meaningfully higher. Read the full article on Seeking AlphaSeeking Alpha • Mar 15
AbCellera: Burning Cash, Searching For 'Blockbusters'
Summary AbCellera's revenues plummeted post-COVID antiviral sales, leading to a significant net loss and an 85% drop in share price, now at ~$2.5. The company is pivoting to develop its own drug pipeline, with ABCL635 and ABCL575 in late-preclinical stages, targeting metabolic and inflammatory conditions. Financially, AbCellera has ~$840 million in liquidity, but its market cap is lower than its cash reserves, reflecting skepticism about its assets. The company's future hinges on successfully developing a blockbuster drug, with key catalysts not expected until 2026, making its current valuation a gamble. Read the full article on Seeking AlphaSeeking Alpha • Dec 23
AbCellera Biologics: Still A Concept Stock
Summary Today, we revisit a somewhat unique developmental company called AbCellera Biologics Inc. The company is moving towards focusing more on its wholly owned candidates off its platform rather than partnerships. The company has myriad very early-stage assets in development, and ABCL stock trades near the net cash on its balance sheet. An updated analysis around AbCellera Biologics follows in the paragraphs below. Read the full article on Seeking AlphaAnalyseartikel • Nov 07
AbCellera Biologics Inc. (NASDAQ:ABCL) Just Reported And Analysts Have Been Cutting Their Estimates
It's shaping up to be a tough period for AbCellera Biologics Inc. ( NASDAQ:ABCL ), which a week ago released some...Seeking Alpha • Oct 14
AbCellera: A Platform To Pipeline Transition
Summary AbCellera is shifting its focus from a platform biotech company to its internal drug pipeline. The company's lead asset, ABCL575, comes with a variety of risks, but in our opinion, has a value of a little over $1B and is derisked based on comparable therapeutics. AbCellera is on track to submit ABCL575 for clinical trials in Q22025, helping the market reset its valuation on the company closer to the value of the lead asset. Read the full article on Seeking AlphaSeeking Alpha • Aug 23
AbCellera: A Waiting Game With High Uncertainty
Summary AbCellera’s Q2 2024 revenue declined by 27% year-over-year to $7.3 million. The company’s net loss widened to $36.9 million due to increased R&D expenses. AbCellera’s cash and marketable securities totaled $697.6 million, with total liquidity exceeding $900 million. The number of molecules in clinical trials increased from nine to 14 within a year. A "hold" recommendation is maintained due to the speculative and high-risk nature of AbCellera’s business. Read the full article on Seeking AlphaAktionärsrenditen
| ABCL | US Life Sciences | US Markt | |
|---|---|---|---|
| 7D | -4.7% | -1.9% | -1.0% |
| 1Y | 143.6% | 25.1% | 14.1% |
Rendite im Vergleich zur Industrie: ABCL übertraf die Branche US Life Sciences , die im vergangenen Jahr eine Rendite von 25.1 erzielte.
Rendite vs. Markt: ABCL übertraf den Markt US, der im vergangenen Jahr eine Rendite von 14.1 erzielte.
Preisvolatilität
| ABCL volatility | |
|---|---|
| ABCL Average Weekly Movement | 15.5% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiler Aktienkurs: Der Aktienkurs von ABCL war in den letzten 3 Monaten im Vergleich zum US -Markt volatil.
Volatilität im Zeitverlauf: ABCLDie wöchentliche Volatilität (16%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der US Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 2012 | 562 | Carl Hansen | www.abcellera.com |
AbCellera Biologics Inc. befasst sich mit der Erforschung und Entwicklung von Antikörper-basierten Arzneimitteln für Indikationen mit ungedecktem medizinischem Bedarf in den Vereinigten Staaten. Das Leitprodukt des Unternehmens ist ABCL635, ein nicht-hormonelles Arzneimittel, das sich derzeit in einer klinischen Phase-2-Studie zur Behandlung mittelschwerer bis schwerer vasomotorischer Symptome befindet; sowie ABCL575, ein vollhumaner monoklonaler Antikörper mit verlängerter Halbwertszeit, der sich in einer klinischen Phase-1-Studie zur Behandlung von T-Zell-vermittelten Autoimmunerkrankungen wie beispielsweise atopischer Dermatitis befindet. Das Unternehmen unterhält eine Forschungskooperation und eine Lizenzvereinbarung mit Eli Lilly and Company, AbbVie Inc. sowie Jazz Pharmaceuticals plc zur Entwicklung multispecifischer T-Zell-bindender Antikörper (TCEs); eine Partnerschaftsvereinbarung mit Viking Global Investors & ArrowMark Partners sowie Biogen Inc.; sowie mit Vertex Pharmaceuticals Incorporated zur Erforschung, Entwicklung, Herstellung und Vermarktung multispecifischer T-Zell-Binder (TCEs) für Autoimmunerkrankungen und andere Erkrankungen.
AbCellera Biologics Inc.'s Grundlagenzusammenfassung
| ABCL grundlegende Statistiken | |
|---|---|
| Marktanteil | US$3.53b |
| Gewinn(TTM) | -US$164.66m |
| Umsatz(TTM) | US$66.17m |
53.3x
Kurs-Umsatz-Verhältnis-21.4x
Kurs-Gewinn-Verhältnis Ist ABCL zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| ABCL Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$66.17m |
| Kosten der Einnahmen | US$197.77m |
| Bruttogewinn | -US$131.60m |
| Sonstige Ausgaben | US$33.06m |
| Gewinn | -US$164.66m |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | -0.51 |
| Bruttomarge | -198.88% |
| Nettogewinnspanne | -248.84% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich ABCL auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/09/12 18:34 |
| Aktienkurs zum Tagesende | 2026/09/11 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das , das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
AbCellera Biologics Inc. wird von 13 Analysten beobachtet. 8 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Guyn Kim | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |
| Steven Seedhouse | Cantor Fitzgerald & Co. |